At presentation, the patient had severe oral pain, dysphagia, ulceration and intermittent bleeding associated with a progressively enlarging left maxillary lesion. She had lost 5 kg over approximately two weeks, weighing 70 kg despite a body mass index of 26.7 kg/m², and had an Eastern Cooperative Oncology Group performance status of 3. The treating team clinically assessed frailty from her rapid weight loss, reduced intake, functional limitations and cardiovascular comorbidities; no validated frailty instrument or baseline frailty score was recorded, and the authors cautioned that improvement should not be equated with documented reversal of frailty.

Biopsy confirmed well-differentiated squamous cell carcinoma. Immunohistochemistry showed negative p16, positive epidermal growth factor receptor expression and a programmed death ligand 1 combined positive score of 70. Contrast-enhanced computed tomography showed an approximately 44 × 42 mm left maxillary lesion with adjacent facial soft-tissue extension and destruction of the anterior and inferior maxillary sinus walls. Multiple ipsilateral cervical nodes were enlarged and considered suspicious, and the pretreatment clinical stage was recorded as cT4aN1M0. The tumor was considered anatomically resectable, but immediate extensive surgery and flap reconstruction were deferred because of concerns about the patient’s limited physiological reserve.

Because cisplatin was considered unsuitable because of poor performance status, nutritional compromise, clinically assessed frailty and cardiovascular comorbidities, the multidisciplinary team selected a chemotherapy-free preoperative regimen. Treatment began on 16 October 2025 with pembrolizumab 200 mg every three weeks and nimotuzumab 200 mg weekly. The rationale included the tumor’s high PD-L1 combined positive score and EGFR positivity, although the report states that this biomarker combination does not establish a validated treatment-selection rule. Supportive care included nutritional support, analgesia, oral care, correction of fluid or electrolyte disturbances, cardiovascular optimization and functional prehabilitation as tolerated. No grade 2 or higher immune-related adverse events or infusion reactions were reported during the neoadjuvant period.

After two treatment cycles, oral pain had largely resolved and the patient could eat independently. Her weight increased from 70 to 75 kg, performance status improved from 3 to 1, albumin rose from 32 g/L to 38 g/L, prealbumin increased from 125 mg/L to 235 mg/L and C-reactive protein declined from 38 mg/L to 6 mg/L. These laboratory changes accompanied the clinical improvement, but the report notes that albumin and prealbumin are influenced by inflammation and are not stand-alone measures of nutritional status. The available measurements also do not demonstrate recovery of muscle mass.

Computed tomography restaging showed marked regression of the primary tumor and reduced cervical lymphadenopathy, reported as a partial response under RECIST 1.1. Following the improvement in nutritional and functional status, the patient underwent maxillectomy and left neck dissection of levels Ia–IV on 12 December 2025. Frozen-section margins were negative, and no flap reconstruction was performed. The stated considerations for omitting flap reconstruction included her advanced age and limited physiological reserve; the report does not provide detailed postoperative morbidity or objective functional outcomes.

Final postoperative pathology was reported as ypT0N0, with no metastatic carcinoma in any of the 32 dissected lymph nodes: 0/10 at levels Ia–Ib, 0/10 at level II, 0/4 at level III and 0/8 at level IV. One node showed necrosis and dystrophic calcification compatible with treatment effect. However, the pathological narrative also described scattered degenerative atypical epithelial clusters interpreted as regressed carcinoma, and the report states that the original slides and final pathology record require confirmation before the complete pathological response is regarded as unequivocally established. Pretreatment nodal involvement was suspected radiologically rather than confirmed by biopsy, so the 0/32 result does not by itself demonstrate clearance of histologically confirmed nodal metastases.

Based on the negative resection margins and absence of metastatic carcinoma in the dissected nodes, the multidisciplinary team did not recommend postoperative radiotherapy or cytotoxic chemotherapy. The patient received maintenance immunotherapy, which was ongoing at the last reported follow-up in September 2026, approximately nine months after surgery. Assessments were conducted at one, three and six months after surgery, and no recurrence was reported at the last follow-up. The short follow-up does not permit conclusions about survival benefit or durable disease control, and the single case cannot validate the omission of postoperative radiotherapy in other patients.

The report emphasizes that recovery of access to surgery was the principal educational value, rather than pathological response alone. Because tumor-directed treatment and supportive care were provided concurrently, their separate contributions to improved intake, weight and performance status cannot be determined. The case also does not show that the antibody combination was necessary for surgery to become feasible, establish the independent contribution of either drug, or support reducing surgical margins, omitting neck dissection or withholding indicated local treatment. The authors state that the bridge-to-surgery concept warrants prospective evaluation in carefully selected patients, with assessment of treatment completion, nutritional intake, physical function, time to surgery, operative morbidity, pathological response, postoperative treatment delivery and longer-term disease control.

Subject of Research: A case report of neoadjuvant pembrolizumab plus nimotuzumab as a bridge to surgery for oral squamous cell carcinoma in a frail 75-year-old patient.

Article Title: Neoadjuvant pembrolizumab plus nimotuzumab as a bridge to surgery in a frail elderly patient with maxillary gingival and palatal squamous cell carcinoma: a case report

Article References: Lin, Q., Shang, L., Guo, Z.-Z., Wang, F., Li, B., Cai, B., Feng, L., Zhang, H., Song, Z., Wu, Z., & Xi, Q. (2026). Neoadjuvant pembrolizumab plus nimotuzumab as a bridge to surgery in a frail elderly patient with maxillary gingival and palatal squamous cell carcinoma: a case report. Frontiers in Oncology, 16, Article 1993693. https://doi.org/10.3389/fonc.2026.1993693

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1993693

Keywords: case report, oral squamous cell carcinoma, neoadjuvant immunotherapy, pembrolizumab, nimotuzumab, frailty, maxillectomy, pathological response, Neoadjuvant, plus, bridge, surgery

The scale of breast cancer in the United States helps explain why clinical research investment remains so urgent. Breast cancer is the most commonly diagnosed cancer among American women apart from skin cancers, accounting for roughly one in three new cancer diagnoses in women each year. The American Cancer Society projects about 320,000 new cases in 2026. While those numbers are sobering, they sit alongside one of the most encouraging long-term trends in all of oncology: breast cancer death rates have fallen steadily since 1989, declining by 44 percent through 2023. Researchers attribute that decline to a combination of earlier detection through screening mammography, growing public awareness, and successive waves of treatment advances, many of which were validated in large, practice-changing clinical trials.

Incidence, however, tells a more complicated story. Diagnosis rates have risen by about 1 percent annually in recent years, and the increase has been somewhat steeper among women younger than 50, at roughly 1.4 percent per year. That trend has intensified scientific interest in why younger women are being diagnosed more often, and it underscores the importance of trials that address the unique needs of different patient populations, from young adults facing hereditary risk to long-term survivors managing the late effects of treatment. Today, approximately 4 million people in the United States are living as breast cancer survivors, a population whose health needs extend well beyond the end of active therapy.

The infrastructure behind much of this progress is less visible to the public than any single drug approval. The Alliance for Clinical Trials in Oncology, a member of the National Cancer Institute’s National Clinical Trials Network, unites more than 26,000 cancer specialists at 112 main institutions and 1,400 affiliated sites across the United States and Canada. More than 40,000 participants have enrolled in Alliance studies over the years, and the organization’s biospecimen repository now holds more than 1.5 million samples collected across three decades. That repository is a scientific resource in its own right, allowing researchers to ask questions about tumor biology, treatment response, and long-term outcomes that were never anticipated when the original trials were designed.

Currently, the Alliance and its partner organization Alliance Foundation Trials have eight active breast cancer trials open to patients and survivors. Together they illustrate the breadth of modern breast cancer research, which spans not only drug development but also de-escalation of therapy, survivorship care, prevention, and early detection. Several of these trials reflect a growing recognition that sometimes the most patient-centered question is not which new drug to add, but whether existing treatment can safely be shortened or reduced.

One example is a phase III study known as OptimICE-PCR, led by Sara Tolaney of Dana-Farber Cancer Institute. It focuses on patients with early-stage triple-negative breast cancer, an aggressive subtype that lacks the three receptors most commonly targeted by therapy. Many of these patients now receive chemotherapy combined with pembrolizumab, an immune checkpoint inhibitor, before surgery, and those who achieve a pathologic complete response, meaning no residual invasive cancer is found at the time of surgery, currently continue pembrolizumab for up to 27 weeks afterward. The trial asks whether observation alone can match that standard in preventing recurrence, potentially sparing responders months of immunotherapy and its associated side effects and costs.

A parallel de-escalation question is being asked in HER2-positive disease. ShortStop-HER2, led by Adrienne Waks of Dana-Farber, enrolls patients whose tumors respond completely to chemotherapy paired with HER2-targeted antibodies before surgery. The standard adjuvant course of HER2-directed therapy has long been 12 months, but prolonged antibody treatment can cause side effects, and some patients struggle to complete the full year. The trial compares six months of HER2-targeted therapy with the conventional 12-month course to determine whether the shorter duration preserves effectiveness while lightening the burden of care. Studies like these reflect a broader movement in oncology toward individualizing treatment intensity, intensifying therapy for those at highest risk and reducing it for those who may not need it.

Not all trials aim to subtract treatment; some aim to target it more precisely. AFT-70 NAVIGATE, co-led by Komal Jhaveri of Memorial Sloan Kettering Cancer Center and Gaorav Gupta of UNC Lineberger Comprehensive Cancer Center, tests a molecular residual disease-guided strategy in intermediate- and high-risk ER-positive, HER2-negative early breast cancer. Patients receive giredestrant, an investigational next-generation oral selective estrogen receptor degrader, while undergoing ongoing Signatera molecular residual disease monitoring, a blood-based test that looks for traces of tumor DNA. If molecular evidence of residual cancer appears, patients may be intensified with a CDK4/6 inhibitor. The goal is to reserve prolonged combination therapy for patients whose biology suggests they need it, rather than exposing everyone to it by default. This approach exemplifies how liquid biopsy technology is reshaping adjuvant treatment design.

Survivorship research occupies another important corner of the portfolio. The Revitalize trial, led by Maryam Lustberg of Yale University Comprehensive Cancer Center, evaluates fractional CO2 laser therapy for vaginal atrophy in breast cancer survivors. Vaginal dryness is a common consequence of menopause, but it is frequently induced or worsened by breast cancer treatments, particularly endocrine therapies such as tamoxifen and aromatase inhibitors. Because hormone-based remedies are often avoided in breast cancer patients, nonhormonal options carry real clinical significance, and symptoms like these are a major reason survivors discontinue the endocrine therapy that protects them from recurrence.

Physical function is the focus of the DEFEND study, led by Kathryn Schmitz of UPMC Hillman Cancer Center and Jennifer Ligibel of Dana-Farber. Chemotherapy can erode strength, endurance, and independence, and fatigue is among the most commonly reported and least adequately treated side effects of cancer care. DEFEND tests whether a structured exercise program delivered entirely through telehealth can help patients receiving chemotherapy maintain physical function, reduce fatigue, and prevent disability. If successful, the trial could expand access to exercise oncology services for patients who live far from specialized cancer centers or face transportation and scheduling barriers.

Prevention and early detection round out the research agenda. A trial led by Devon Noonan of Duke University School of Medicine tests a text-based smoking cessation program against a printed manual in rural cancer patients and survivors who smoke, including people with breast cancer. Continued smoking after a cancer diagnosis is associated with worse outcomes, yet rural populations face persistent barriers to cessation services, and a scheduled, gradual-reduction approach delivered by text message could reach people that traditional programs miss.

Another study, led by Marie Wood of the University of Colorado School of Medicine, addresses an emerging frontier in cancer screening: multicancer early detection blood tests. These tests, which aim to identify cancer signals in a single blood draw, are advancing rapidly, but evaluating them rigorously requires large, well-characterized reference sets of samples from people with and without cancer. By collecting and storing blood and tissue specimens from both groups, the study creates a blinded reference resource that can support the development and validation of tests intended to catch cancers, including breast cancer, at earlier and more treatable stages.

Genetic services are the subject of a trial led by Angela Bradbury of the University of Pennsylvania Abramson Cancer Center. Genetic testing for inherited cancer syndromes is an established standard of care that can guide enhanced screening and risk-reduction strategies, yet many adolescents and young adults with cancer never receive recommended counseling and testing. The study compares a digital, chatbot-enabled delivery model with standard remote genetic services to determine whether the technology can increase uptake among this population while easing demands on genetic counselors and other health care staff. Because hereditary risk information has implications for patients’ relatives as well, improving access to these services can ripple outward through entire families.

Viewed together, these eight trials sketch the trajectory of the field. Treatment is becoming simultaneously more effective and more tailored, with immunotherapy de-escalation, shortened antibody courses, and molecular residual disease-guided intensification all under formal evaluation. Care is extending beyond the tumor to encompass sexual health, physical function, and behavioral risk factors. And the tools of early detection, from multicancer blood tests to digitally delivered genetic services, are being tested with the same rigor once reserved for drugs. The nearly 1,900 breast cancer publications the Alliance has produced from its studies testify to how much evidence this cooperative model has generated, and each new trial depends on the patients, families, and investigators willing to participate. Their contributions remain the foundation on which the next generation of breast cancer advances will be built.

Subject of Research: Breast cancer clinical trials advancing treatment, prevention, and early detection research

Article Title: Breast Cancer Awareness Month: Advancing breast cancer research through clinical trials

Article References: Breast Cancer Awareness Month: Advancing breast cancer research through clinical trials. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: breast cancer, clinical trials, Breast Cancer Awareness Month, Alliance for Clinical Trials in Oncology, triple-negative breast cancer, HER2-positive breast cancer, immunotherapy, early detection, cancer survivors, National Cancer Institute, pembrolizumab, genetic testing

The trial, registered as NCT03546361, was built on a deceptively simple biological premise. Dendritic cells are the sentinels of the immune system: they sample material from their surroundings, process it, and present fragments of it to T cells, instructing those T cells on what to attack. In cancer vaccines, dendritic cells can be harvested from a patient, loaded or modified to carry tumor-associated signals, and returned to the body. The UCLA-led team went a step further by engineering the cells to express CCL21, a chemokine, or chemical attractant, that is normally produced in lymph nodes and serves to guide circulating lymphocytes toward sites where antigens are being presented. The hope was that injecting these CCL21-producing cells directly into lung tumors would convert the tumor itself into something resembling a lymph node, a beacon that would pull T cells out of circulation and into the tumor microenvironment, where they could recognize and destroy cancer cells.

Pembrolizumab was the second component of the strategy. The drug is an antibody that blocks PD-1, a receptor on T cells that functions as a molecular brake. Many tumors exploit this brake, inducing T cells that reach the tumor to become exhausted and inactive. By releasing the brake, pembrolizumab and other PD-1 pathway inhibitors have transformed the treatment of non-small cell lung cancer, the most common form of lung malignancy. But resistance is common: many patients never respond, and many who initially respond eventually progress. The rationale for combining the two approaches was complementary. The CCL21 vaccine was designed to increase the number and diversity of T cells entering the tumor, while pembrolizumab was intended to keep those newly arrived cells functional once inside. Each addressed a different point of failure in the anti-tumor immune response.

The trial was structured in two stages, following the conventional design of early-phase oncology studies. In the dose escalation phase, eleven patients received progressively larger quantities of the CCL21-modified dendritic cells, injected directly into tumors under image guidance, alongside standard pembrolizumab. The goal was to identify the maximum administered dose, the highest dose that could be given safely. That dose was determined to be 3 times 10 to the seventh cells per injection. A further twelve patients were then treated at this dose in a dose expansion cohort, bringing the total to twenty-three participants with advanced non-small cell lung cancer. Throughout, the investigators monitored safety, tumor response by imaging criteria, and, critically, changes in the immune landscape of the tumors themselves through serial biopsies.

On the safety front, the news was encouraging. The combination was well tolerated, an important finding for a cell-based therapy delivered directly into tumors. But the efficacy results were disappointing. No objective responses were recorded; not one patient experienced the degree of tumor shrinkage that would qualify as a partial or complete response under standard criteria. The trial therefore failed to meet its primary endpoint, the objective response rate. There was, however, a signal of modest activity: 36.8 percent of patients achieved a best response of stable disease, meaning their tumors neither grew substantially nor shrank. In advanced lung cancer, where untreated disease progresses relentlessly, disease stability is not nothing, but it falls far short of the durable regressions that checkpoint inhibitors can produce in responsive patients.

The most scientifically rich portion of the study came from the post-hoc analyses of longitudinal tumor biopsies, collected before and after treatment. Using modern genomic techniques, the researchers tracked how the cellular composition of the tumors changed over the course of therapy. They found that the vaccine-pembrolizumab combination did what it was designed to do at the level of cell traffic: tumors showed increased infiltration by CD4-positive T cells, the helper subset of the immune system, and by novel T cell clones, meaning T cells with receptors that had not previously been detected in the tumor. In other words, new immune recruits, cells that had not been patrolling the tumor before, were arriving after treatment. The chemokine beacon, at least in this respect, worked.

The biopsy data also revealed why some patients fared better than others, at least in terms of disease stability. Patients whose tumors remained stable showed greater T cell receptor diversity, a broader repertoire of distinct T cell specificities within the tumor, and greater expansion of novel clones following therapy. This pattern is consistent with a long-standing principle of tumor immunology: a diverse, polyclonal T cell response is harder for a tumor to escape than a narrow one, and the arrival of fresh clones suggests that the vaccine was genuinely educating and recruiting new immune specificities rather than merely amplifying cells already present. Disease stability, in this framing, was not a random outcome but the visible footprint of a broader and more dynamic immune response.

Yet the deeper analyses exposed two fundamental problems that likely prevented immune infiltration from becoming tumor destruction. First, many of the novel T cell clones that appeared after treatment failed to persist over time. They arrived, and then they faded, suggesting that the tumor environment could not sustain them, whether because their target antigens were absent, their stimulation was insufficient, or suppressive forces eliminated them. Second, the researchers identified immunosuppressive myeloid signaling signatures across multiple time points. Myeloid cells, a family of innate immune cells that includes macrophages and myeloid-derived suppressor cells, are notorious architects of the immunosuppressive tumor microenvironment. Their persistent signaling presence indicates that the vaccine strategy had not reprogrammed this suppressive layer, leaving newly recruited T cells to operate in a hostile terrain.

The investigators themselves framed the outcome with characteristic precision: CCL21 dendritic cell vaccination combined with pembrolizumab can promote T cell infiltration, but this did not translate into meaningful clinical efficacy, potentially because the T cell response lacked sufficient tumor specificity and because the therapy could not fully reprogram the tumor microenvironment. That distinction between tumor specificity and general immune activation is crucial. Recruiting T cells into a tumor is only useful if those T cells recognize antigens carried by the cancer cells. A vaccine that draws in T cells of uncertain or irrelevant specificity may fill a tumor with immune cells that look impressive under the microscope but cannot kill the malignant cells around them. Combined with an unreformed myeloid compartment actively dampening immunity, the result is cellular traffic without cellular warfare.

For the field, the trial is best read as a rigorous map of a failure mode rather than a dead end. It demonstrates that intratumoral chemokine-engineered dendritic cells are feasible, safe, and biologically active, and it provides a template for measuring whether next-generation designs actually change the tumor microenvironment. Future efforts will likely need to ensure that recruited T cells are directed against true tumor antigens, perhaps through personalized neoantigen targeting, and to pair vaccination with agents that neutralize myeloid-mediated suppression. The patients who enrolled, and the detailed molecular record their tumors provided, have converted a negative efficacy result into a detailed hypothesis about what a successful version of this strategy must overcome. In immunotherapy, as this study makes plain, getting immune cells through the door is only the first step; keeping them there, aimed at the right targets, and unopposed by the tumor’s defenses is the far harder task ahead.

Subject of Research: A phase I trial of a CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer

Article Title: A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Article References: Oh, M. S., Lisberg, A. E., Dumitras, C., Tran, L. M., Salehi-Rad, R., Krysan, K., Lim, R. J., Shabihkhani, M., Romero, T., Li, S., Zeng, W., Jing, Z., Li, R., Kahangi, B. P., Tsvetkova, O., Suh, R. D., Abtin, F., Genshaft, S. J., Oh, S. S., … Dubinett, S. M. (2026). A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial. Nature Communications. https://doi.org/10.1038/s41467-026-78130-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78130-7

Keywords: CCL21, dendritic cell vaccine, pembrolizumab, non-small cell lung cancer, immunotherapy, phase I trial, T cell infiltration, tumor microenvironment, immune checkpoint inhibitors, myeloid suppression, T cell receptor diversity, cancer vaccine

The case, published in Frontiers in Drug Discovery by Ju Hye Kim, Ji Yeon Chung, and Jeong Bin Bong, centers on a 65-year-old man with a layered oncological history. Twelve years before presentation he had undergone a total thyroidectomy for thyroid cancer and a thymectomy for thymoma, a tumor of the thymus gland that sits behind the sternum and plays a central role in immune education. One year before the current episode he was diagnosed with bladder cancer, treated with a radical cystectomy, and started on adjuvant pembrolizumab every three weeks. Four weeks after the first infusion, roughly a week after his second dose, he began to notice double vision, slurred speech, difficulty swallowing, and shortness of breath. Over the following two months these symptoms progressed steadily, interfering with eating and sleeping, until he required hospital admission.

Neurological examination on admission revealed a pattern classic for myasthenia gravis but with an unusual distribution. The patient displayed external ophthalmoplegia, meaning his eyes could not move normally in any direction, along with bilateral ptosis, or drooping of both eyelids. His speech was dysarthric and his swallowing impaired, yet his limb strength was essentially preserved and deep tendon reflexes were normal. Arterial blood gas analysis showed a low partial pressure of oxygen at 68.6 mmHg against a normal range of 83 to 108 mmHg, with oxygen saturation of 93.2 percent, indicating respiratory compromise despite normal carbon dioxide clearance. Pulmonary function testing was more alarming still: forced vital capacity had fallen to 40 percent of predicted and forced expiratory volume in one second to 44 percent of predicted, a pattern consistent with severe neuromuscular respiratory weakness rather than intrinsic lung disease.

The diagnostic workup then took a decisive turn. Creatine kinase, the enzyme that rises when skeletal muscle is destroyed, measured 185 U/L, comfortably within the reference range of 37 to 212 U/L. Cardiac injury markers told a similar story: creatine kinase-MB at 2.31 ng/mL, myoglobin at 33.56 ng/mL, and troponin I below 0.01 ng/mL were all normal, and both the electrocardiogram and transthoracic echocardiography, which showed an ejection fraction of 64 percent, were unremarkable. This combination effectively excluded myositis and myocarditis, the inflammatory muscle and heart conditions that frequently overlap with checkpoint inhibitor-induced myasthenia and account for much of its mortality. Cerebrospinal fluid analysis showed only a mildly elevated protein of 79.8 mg/dL, brain magnetic resonance imaging was unremarkable, and nerve conduction studies demonstrated normal conduction velocities and amplitudes without abnormal spontaneous activity on electromyography.

Electrophysiological testing did, however, capture the signature of the neuromuscular junction. Repetitive nerve stimulation revealed a mild decremental response of 14 percent at low-frequency stimulation, but only in the trapezius muscle; the orbicularis oculi and abductor digiti minimi muscles showed no significant decrement. The ice-cube test, a bedside maneuver in which cooling temporarily improves myasthenic weakness, was negative, while the neostigmine test produced a modest improvement in bilateral ptosis. On the second day of hospitalization the patient’s breathing deteriorated to the point that he required transfer to the intensive care unit and initiation of noninvasive positive-pressure ventilation. Clinicians suspected pembrolizumab-induced myasthenia gravis and began a three-day course of 500 mg of intravenous methylprednisolone.

Serological testing then revealed the feature that makes this case exceptional. Antibodies against the acetylcholine receptor, the most common target in myasthenia gravis, were negative, as were antibodies against muscle-specific kinase, or MuSK, and against gangliosides. But the paraneoplastic syndrome panel returned a positive result for anti-titin antibodies, autoantibodies directed against titin, an enormous structural protein that provides skeletal muscle with its elastic properties. Anti-titin antibodies belong to the heterogeneous family of anti-striational antibodies, which also include antibodies against ryanodine receptors and the voltage-gated potassium channel Kv1.4. They are classically associated with thymoma-related myasthenia gravis and have been linked to more severe disease progression and greater muscle involvement, yet in this patient they appeared in complete isolation, without the muscle destruction that their presence might have predicted.

Treatment unfolded in a way that carries practical lessons. High-dose corticosteroids failed to produce meaningful clinical improvement, but intravenous immunoglobulin, administered at 2 g/kg over five days, led to visible clinical benefit by the third day of infusion. The patient was discharged with gradual improvement and continued on oral prednisolone, though steroid therapy ultimately had to be discontinued when bleeding from a duodenal ulcer, considered steroid-related, intervened. He has since remained on monthly intravenous immunoglobulin as maintenance therapy, and at five-month follow-up his Myasthenia Gravis-Activities of Daily Living score stood at 7, reflecting sustained overall clinical improvement. The authors note that while no conclusions about treatment efficacy can be drawn from a single patient, this experience supports prior reports suggesting that early use of intravenous immunoglobulin or plasma exchange may benefit selected patients with checkpoint inhibitor-related myasthenia gravis.

To place their patient in context, the team systematically reviewed published cases of checkpoint inhibitor-related myasthenia gravis with anti-striational antibody positivity, compiling twelve cases including their own. The picture that emerged was sobering. In the majority of reported cases there was no history of thymoma, and several patients presented with the dreaded overlap of myasthenia gravis, myositis, and myocarditis, a triad associated with rapid deterioration and death within days to weeks. Of the twelve patients, four died, including a 77-year-old woman treated with nivolumab who succumbed 29 days after presentation and an 87-year-old man treated with atezolizumab who died within three days. Only one other case, described by Lara and colleagues in 2019, involved a patient with a remote thymectomy, and in that instance only a generic anti-striational antibody titer was reported without specification of the anti-titin subtype. No previously published case combined anti-titin antibody positivity with a documented thymoma history, making the present report the first of its kind.

The temporal relationship between thymectomy and disease onset raises deep immunological questions. The thymus is the site where T cells learn to distinguish self from non-self, and thymomas disrupt this process in ways that predispose to autoimmunity. Approximately 20 percent of patients diagnosed with thymoma have myasthenia gravis, and conversely, thymoma is frequently discovered during the evaluation of newly diagnosed myasthenia. Rare reports have documented myasthenia gravis appearing years after thymectomy for thymoma, and the authors of the present case propose that autoreactive T cells or long-lived plasma cells may persist in the periphery long after the thymoma is removed, remaining dormant until PD-1 blockade removes the inhibitory signals that keep them in check. A previous report described pembrolizumab-induced myasthenia gravis occurring fifteen years after thymectomy, lending plausibility to this model of reactivation after prolonged quiescence.

The authors are careful to acknowledge the limits of a single case. Causality between isolated anti-titin antibody positivity and the clinical phenotype cannot be established from one patient, and the anti-titin antibody testing was qualitative, precluding any assessment of whether antibody titers tracked with disease activity. Nevertheless, the case expands the recognized immunological spectrum of checkpoint inhibitor-related myasthenia gravis and carries a clear clinical message: patients with a history of thymoma who receive immune checkpoint inhibitors warrant careful neurological vigilance, and clinicians should consider anti-striational antibody testing, including anti-titin antibodies, when myasthenic symptoms emerge in this population, even when conventional acetylcholine receptor and MuSK assays come back negative. As checkpoint inhibitors continue to expand across tumor types, the population of thymectomy survivors exposed to these drugs will only grow, and this case suggests that the immunological legacy of the thymus can resurface with surprising force, more than a decade after the gland itself is gone.

Subject of Research: Pembrolizumab-induced myasthenia gravis with isolated anti-titin antibody positivity after thymectomy for thymoma

Article Title: Case Report: Pembrolizumab–induced myasthenia gravis with isolated anti-titin antibody positivity after thymectomy for thymoma

Article References: Kim, J. H., Chung, J. Y., & Bong, J. B. (2026). Case Report: Pembrolizumab–induced myasthenia gravis with isolated anti-titin antibody positivity after thymectomy for thymoma. Frontiers in Drug Discovery, 6, Article 1932554. https://doi.org/10.3389/fddsv.2026.1932554

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1932554

Keywords: pembrolizumab, immune checkpoint inhibitors, myasthenia gravis, anti-titin antibody, thymoma, thymectomy, immune-related adverse events, PD-1 inhibitor, intravenous immunoglobulin, neuromuscular junction, paraneoplastic antibodies, bladder cancer

Extravasation is the accidental leakage of intravenously administered medication into the tissue surrounding a vein rather than into the bloodstream itself. It is a recognized complication of chemotherapy, but its consequences vary enormously depending on the drug involved. Some agents are irritants that provoke localized inflammation and pain, while others are vesicants capable of causing severe blistering, ulceration, and deep tissue death. Enfortumab vedotin belongs to the class of antibody-drug conjugates, molecules engineered to deliver a cytotoxic payload directly to tumor cells. In this case, the payload is monomethyl auristatin E, a potent antimitotic agent that disrupts microtubule assembly and halts cell division. Because of this cytotoxic cargo, the authors argue that enfortumab vedotin in particular may pose a high risk of severe local complications when it extravasates.

The clinical course in this patient illustrates just how destructive such an event can be. During the first treatment cycle, the port catheter, which had been inserted into the cephalic vein to provide reliable central venous access, became dislodged from its intended position. The infusate then escaped into the subcutaneous tissue of the infraclavicular region, the area just below the collarbone. What followed was extensive subcutaneous necrosis, the death of a broad zone of tissue beneath the skin. Conservative measures alone could not contain the damage, so the surgical team performed debridement, removing the dead tissue, and applied a vacuum-assisted closure system, a device that applies controlled negative pressure to promote wound healing. The wound then healed by secondary intention, a slower process in which the body fills the defect with new tissue from the base upward.

Despite the severity of the injury, the outcome was ultimately favorable in functional terms. The wound closed with a residual scar, but the patient experienced no lasting pain and no impairment of arm or shoulder movement. Treatment was not abandoned. Instead, the oncology team resumed the EV-P regimen through a peripheral venous catheter, a simpler line placed in a peripheral vein, and the patient went on to achieve a deep partial response, meaning his metastatic disease regressed substantially under therapy. Written informed consent was obtained from the patient for publication of the clinical data, and the authors note that local ethics committee approval was not required because the report documents clinical treatment and its complications rather than a research project involving human subjects.

The significance of this case extends beyond a single patient. The EV-302/KEYNOTE-A39 study demonstrated that combining enfortumab vedotin with pembrolizumab produces superior outcomes in metastatic urothelial carcinoma compared with platinum-based chemotherapy, and the regimen has since been adopted as a new first-line standard. With rapidly increasing use worldwide, the Münster team emphasizes that documenting and publishing unexpected side effects and complications is essential to systematize procedures for managing them. Until now, the literature on EV-P extravasation has been essentially empty, leaving clinicians without evidence-based guidance on how to recognize, grade, and treat such events. This report, together with a mini review of the current literature, begins to fill that gap.

The technical anatomy of enfortumab vedotin helps explain the danger. The molecule consists of a monoclonal antibody targeting Nectin-4, a cell adhesion protein abundantly expressed on urothelial cancer cells, linked to monomethyl auristatin E through a cleavable linker. When the antibody binds its target and the conjugate is internalized, the payload is released inside the tumor cell, where it destroys the microtubule network and triggers cell death. This targeted delivery is what makes the drug so effective against bladder cancer, but it also means that any drug escaping into healthy subcutaneous tissue carries a cytotoxic weapon. Tissue exposed to monomethyl auristatin E can undergo the same kind of cell death that the drug inflicts on tumors, producing necrosis rather than simple inflammation.

Pembrolizumab, by contrast, is a monoclonal antibody without a cytotoxic payload. It works by blocking the PD-1 receptor on T cells, releasing the brakes that tumors place on the immune system. As a pure immunotherapy, it is generally considered less likely to cause severe local tissue damage on extravasation, although any large-volume infusion into tissue can provoke irritation. The combination regimen therefore presents a mixed risk profile, with enfortumab vedotin as the dominant concern for local complications. The authors stress that because of its cytotoxic payload, EV in particular may pose a high risk of local complications in the context of extravasations, a point with direct implications for infusion practice as the regimen spreads through oncology departments globally.

The route of administration matters as much as the drug itself. Central venous access devices such as implanted ports are widely used in cancer care to protect peripheral veins and allow long-term infusion, but they introduce their own failure modes. Catheter dislocation, as occurred in this patient, can redirect infusate into tissue while the external signs of a properly functioning line remain reassuring. Recognizing an extravasation from a central line can therefore be more difficult than from a peripheral cannula, where swelling and pain at the insertion site are immediately visible. The Münster case, graded 3 under CTCAE criteria, demonstrates that central venous EV-P extravasation can produce damage severe enough to require operative management, a scenario clinicians managing the regimen should now anticipate.

For the growing population of patients receiving EV-P, the practical lessons are concrete. Infusion teams should maintain vigilance for catheter dislocation even with central lines, and any suspicion of leakage should prompt immediate assessment. When necrosis occurs, surgical debridement combined with vacuum-assisted closure offers a pathway to wound healing with acceptable functional outcomes, as this patient’s recovery shows. Crucially, an extravasation event need not end cancer treatment: therapy was successfully resumed via a peripheral venous catheter, and the deep partial response achieved suggests that a severe local complication, managed promptly and systematically, does not necessarily compromise the antitumor effect. As the authors conclude, with increasing use of the regimen, careful documentation of such events is the foundation for standardized procedures, turning isolated case reports into the evidence base that clinicians will need as this powerful combination becomes a global standard of care.

Subject of Research: First reported surgical case of central venous EV-P extravasation in metastatic urothelial carcinoma

Article Title: Management of extravasations of enfortumab vedotin and pembrolizumab: a case report and mini review of the current literature

Article References: Dinkel, H., Seifert, K. E., Bögemann, M., Schrader, A. J., & Schlack, K. (2026). Management of extravasations of enfortumab vedotin and pembrolizumab: a case report and mini review of the current literature. Journal of Cancer Research and Clinical Oncology, 152(10), Article 197. https://doi.org/10.1007/s00432-026-06646-y

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06646-y

Keywords: enfortumab vedotin, pembrolizumab, extravasation, urothelial carcinoma, antibody-drug conjugate, case report, Management, extravasations, enfortumab, vedotin, case, report

The research team, registered prospectively in the PROSPERO database under identifier CRD420261458417, conducted a comprehensive search of PubMed/MEDLINE, the Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials from database inception through 11 July 2026, with source-specific updates completed on 13 and 14 July 2026. Their question was deceptively simple: among adults treated with the lenvatinib-pembrolizumab combination for advanced or recurrent endometrial cancer, do patients who begin lenvatinib at doses below 20 milligrams fare differently from those who start at the full 20-milligram dose? Because no randomized trial has directly addressed this question, the investigators had to rely on comparative observational studies, a class of evidence that comes with well-known vulnerabilities to confounding and selection bias.

To be eligible, studies had to compare patients on different lenvatinib starting doses within the combination regimen. The researchers defined their primary estimand as the contrast between starting doses below 20 milligrams and the standard 20-milligram starting dose, and they deliberately kept a secondary 10-milligram threshold contrast and a separate measure of relative dose intensity during the first eight weeks of treatment apart from the main analysis, recognizing that pooling these distinct exposure definitions would blur clinically meaningful differences. Binary outcomes such as tumor response and adverse events were summarized as risk ratios, while time-to-event outcomes such as progression-free survival were expressed as hazard ratios. This methodological discipline matters, because dose intensity and starting dose are related but not interchangeable concepts, and conflating them is a common pitfall in dose-optimization research.

The search yielded ten studies representing ten independent cohorts and a total of 1,000 patients. Of these, five cohorts encompassing 703 patients provided data for the primary starting-dose comparison, with the specific denominators varying by outcome depending on how completely each study reported its results. The remaining cohorts informed the secondary contrasts or descriptive syntheses. The scale of the evidence base is modest by the standards of modern oncology, where practice-changing trials often enroll thousands of participants, and this limitation echoes throughout the findings.

The headline result concerns antitumor effectiveness. Pooling across the available cohorts, the risk ratio for objective response, meaning measurable tumor shrinkage, was 0.97 for patients starting below 20 milligrams compared with those starting at 20 milligrams, with a 95 percent confidence interval of 0.70 to 1.34 and minimal heterogeneity between studies, indicated by an I-squared value of 11.9 percent. For disease control, which combines complete responses, partial responses, and stable disease, the pooled risk ratio was 0.96 with a confidence interval of 0.83 to 1.11 and essentially no heterogeneity at all, with I-squared at 0 percent. In plain terms, patients who started at reduced doses appeared to derive neither more nor less tumor control than those who started at the full dose, at least as far as these observational data can tell.

The tolerability picture was equally inconclusive. The pooled risk ratio for subsequent lenvatinib dose reduction, an indirect marker of how often patients needed their doses lowered after starting treatment, was 0.66 with a confidence interval spanning 0.34 to 1.27 and modest heterogeneity of 27.4 percent. Although the point estimate hints that reduced-dose starters needed fewer later dose reductions, the confidence interval crosses 1.0 by a wide margin, meaning the data cannot rule out anything from a substantial benefit to a substantial harm. Estimates for treatment interruption, permanent discontinuation, and grade 3 or higher adverse events were similarly imprecise, and two outcomes of obvious practical importance, hospitalization and treatment persistence, could not be pooled at all because the underlying studies reported them in forms too heterogeneous to combine statistically.

Perhaps the most sobering aspect of the analysis is the quality assessment. The researchers evaluated risk of bias using ROBINS-I, a tool specifically designed for non-randomized studies of interventions, and found that every evaluated result carried a serious overall risk of bias. They used ROB-ME to assess bias arising from missing evidence and applied the GRADE framework to rate certainty, concluding that the certainty of evidence was very low for all pooled comparisons. In the GRADE hierarchy, very low certainty means the true effect could differ substantially from the estimate, and the findings should be regarded as tentative at best. This is not a criticism of the review itself but a reflection of the observational evidence it had to work with: clinicians choose starting doses based on patient characteristics such as body weight, comorbidities, and baseline blood pressure, and those same characteristics independently influence outcomes, creating confounding that statistical adjustment can only partially remove.

The authors’ conclusion is measured but pointed: comparative observational evidence does not establish that starting lenvatinib below 20 milligrams preserves antitumor effectiveness or improves tolerability relative to the standard 20-milligram starting dose. They call for prospective, confounder-aware comparative studies before a reduced starting-dose strategy can be recommended broadly. The distinction between

Subject of Research: Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence

Article Title: Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence

Article References: Wu, Y., Wei, J., Chang, C., Li, M., Xu, R., Dong, S., & Jiang, M. (2026). Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence. Frontiers in Oncology, 16, Article 1965694. https://doi.org/10.3389/fonc.2026.1965694

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1965694

Keywords: endometrial cancer, lenvatinib, pembrolizumab, dose optimization, meta-analysis, systematic review, immunotherapy, observational evidence, progression-free survival, drug tolerability, oncology, GRADE certainty

The story began three years before his cancer diagnosis. A routine health examination in 2019 had revealed mild thyroid dysfunction: low total thyroxine (TT4) and total triiodothyronine (TT3), yet a thyroid-stimulating hormone (TSH) level that sat squarely within the normal range. Antibodies against thyroid peroxidase and thyroglobulin, the molecular fingerprints of autoimmune thyroid attack, were dramatically elevated at 1385 and 105 IU/mL respectively, and thyroid ultrasound pointed to Hashimoto’s thyroiditis. Nothing was done at the time, and the patient was not on thyroid hormone replacement when he was diagnosed with middle thoracic esophageal squamous cell carcinoma in April 2022.

On April 15, 2022, he began neoadjuvant therapy combining pembrolizumab with nab-paclitaxel and carboplatin, given every 21 days. Three weeks after the first pembrolizumab dose, his thyroid hormones surged: TT3 climbed to 5.27 nmol/L and TT4 to 164.49 nmol/L while TSH collapsed below the detection limit. This pattern of thyrotoxicosis is the classic opening act of painless thyroiditis, an immune-mediated inflammation in which damaged follicles dump preformed hormone into the bloodstream. Three weeks later the storm reversed, and his thyroid function crashed into overt hypothyroidism, with TT3 at 0.62 nmol/L and TT4 at 14.31 nmol/L while TSH rose to 6.032 mIU/L. Levothyroxine replacement at 50 micrograms daily was started.

Thyroid dysfunction is the most common endocrine immune-related adverse event of PD-1 inhibitors, with reported incidences of 7.0 to 8.5 percent for PD-1 monotherapy and up to 13.2 percent for combination regimens such as nivolumab plus ipilimumab. The prevailing explanation is destructive thyroiditis: PD-L1 and PD-L2 are abundantly expressed on thyroid follicular cells, which may make the gland uniquely vulnerable when checkpoint inhibition removes the brakes on systemic T-cell responses. Typically, a transient hyperthyroid phase precedes permanent hypothyroidism as the gland is progressively destroyed. Patients with pre-existing positive thyroid peroxidase antibodies, as in this case, face a significantly higher risk of developing these events.

What followed was anything but typical. After esophagectomy in July 2022 and further adjuvant chemotherapy, the patient’s TSH climbed to 119.96 mIU/L despite escalating levothyroxine doses, and his thyroid function eventually stabilized on 100 micrograms daily. But at week 31 of pembrolizumab therapy, in November 2022, follow-up testing showed something unexpected: TSH began to fall, dropping below the reference range and eventually to the lower limit of detection, while TT4 fell in parallel. In a patient whose thyroid had been destroyed, a low TSH with low thyroid hormone cannot be explained by the gland itself. It pointed instead to a failing pituitary, the master gland that should be screaming TSH to drive whatever thyroid tissue remains.

When he was referred to endocrinology in March 2023 for profound fatigue and myxedema, the team systematically probed the other pituitary axes. Morning cortisol was normal at 179.64 ng/mL with preserved diurnal rhythm and only mildly elevated ACTH, indicating intact adrenal function. Follicle-stimulating hormone was mildly raised, but the remaining gonadal hormones were normal, and there was no hyponatremia or evidence of diabetes insipidus. Pituitary MRI showed a thinned gland, just 3.5 mm in height, with homogeneous signal, uniform contrast enhancement, no stalk deviation, and no mass lesion. The diagnosis: isolated central hypothyroidism, a condition in which the pituitary’s TSH secretory capacity fails while every other hormonal axis remains intact.

Central hypothyroidism arising after painless thyroiditis and primary hypothyroidism in the same PD-1 inhibitor-treated patient has essentially not been described before. Immune-related hypophysitis, inflammation of the pituitary, occurs in only 0.5 to 1 percent of patients on PD-1 agents and typically emerges late in therapy, with a median onset around 26 weeks, predominantly in older men, often without headache and sometimes with unremarkable imaging. Those features fit this case. But almost all previously documented cases of checkpoint inhibitor hypophysitis involve adrenocortical insufficiency, and hypophysitis presenting exclusively with isolated TSH deficiency has never been reported. Over four years of follow-up, this patient’s adrenal, gonadal, and posterior pituitary function remained intact, while his TSH stayed persistently suppressed, suggesting sustained impairment of the pituitary’s TSH secretory reserve rather than a transient insult.

The authors reconstruct the course in three phases. Before pembrolizumab, the patient already had Hashimoto’s thyroiditis with low TT4 but normal TSH, hinting that mild central hypothyroidism may have predated immunotherapy. In the second phase, destructive thyroiditis produced severe primary hypothyroidism, and notably the compensatory TSH rise was smaller than expected for the degree of free T4 reduction, a subtle clue of a suboptimal pituitary response. In the final phase, with the thyroid pharmacologically controlled, TSH declined progressively to undetectable levels alongside falling TT3 and TT4. The researchers speculate that on the background of pre-existing Hashimoto’s disease and possible subclinical central hypothyroidism, pembrolizumab may have triggered delayed pituitary injury, or perhaps exacerbated a pre-existing lesion rather than initiating it outright.

The case also exposed a practical dosing dilemma rarely discussed in the literature. Levothyroxine is absorbed mainly in the jejunum, and this patient’s post-esophagectomy gastrointestinal remodeling had altered his intestinal anatomy and drug exposure. His dose was titrated to 175 micrograms daily, a figure exceeding the conventional replacement dose for men after total thyroidectomy in the region, yet his total T4 remained mildly low. Switching to a split regimen of 50 micrograms three times daily improved hormone levels, though subsequent monitoring showed recurrent mild free T4 elevations, underscoring how variable bioavailability can be after upper gastrointestinal surgery. For the growing population of cancer survivors living with both esophagectomy and checkpoint inhibitor endocrinopathy, personalized dosing schedules may be essential.

The report carries honest limitations: it is a single retrospective case, the TRH stimulation test was not performed to formally assess pituitary reserve, no biopsy was obtained, and no baseline pituitary MRI existed for comparison. The 15-week gap between the onset of TSH decline and complete pituitary evaluation also means any acute-phase pituitary enlargement, which can appear and resolve within weeks in immune hypophysitis, would have been missed. Even so, the biochemical trajectory, imaging findings, and management challenges offer a valuable lesson for oncologists and endocrinologists alike. Thyroid dysfunction during PD-1 inhibitor therapy is common and usually straightforward, but this case is a reminder that the pituitary can also fall silent, sometimes in isolation, and that pituitary function deserves monitoring alongside the thyroid when checkpoint inhibitors are on board.

Subject of Research: Sequential primary and central hypothyroidism as immune-related adverse events of pembrolizumab therapy

Article Title: Pembrolizumab-associated primary hypothyroidism followed by central hypothyroidism: a case report

Article References: Sun, J., Wang, C., Sun, Z., & Li, W. (2026). Pembrolizumab-associated primary hypothyroidism followed by central hypothyroidism: a case report. Frontiers in Oncology, 16, Article 1978296. https://doi.org/10.3389/fonc.2026.1978296

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1978296

Keywords: pembrolizumab, PD-1 inhibitors, immune checkpoint inhibitors, hypothyroidism, central hypothyroidism, Hashimoto's thyroiditis, painless thyroiditis, hypophysitis, immune-related adverse events, levothyroxine, esophageal cancer, pituitary dysfunction

The science behind IMM60 begins with a molecule that has fascinated immunologists for decades. Alpha-galactosylceramide, a lipid originally isolated from a marine sponge, is the archetypal activator of iNKT cells. These cells occupy a peculiar niche in the immune system: they carry an invariant T cell receptor, a fixed molecular sensor that recognizes lipid fragments displayed by a specialized presenting molecule called CD1d. When the right lipid locks into CD1d and engages the iNKT cell receptor, the result is a rapid, coordinated burst of immune activity. Unlike conventional T cells, which need weeks to expand and specialize against a new threat, iNKT cells respond within hours, releasing signaling proteins that recruit and energize other immune players, including cells that kill tumors directly.

Alpha-galactosylceramide itself, however, has proved awkward as a drug. It is chemically unstable, difficult to formulate, and its potency fades during storage and in the bloodstream. IMM60 was engineered to be a more robust cousin: a synthetic lipid agonist with enhanced potency and stability, encapsulated within liposomes to protect it from degradation and deliver it efficiently to the CD1d presentation machinery. The idea is that a stable, liposomal formulation could finally translate the dramatic immune activation seen in laboratory studies into a therapy that works reliably in patients, potentially priming tumors for attack by the immune system and working hand in hand with existing immunotherapies.

The IMP-MEL trial enrolled fifteen patients with advanced melanoma or non-small cell lung cancer, and fourteen of them received treatment, six with melanoma and eight with lung cancer. Together they received sixty-six infusions of liposomal IMM60, with a median of five infusions per patient and a range of two to six. Some patients received the drug on its own, while others received it in combination with pembrolizumab, an antibody that blocks the PD-1 checkpoint and is already a mainstay of immunotherapy for both tumor types. The combination strategy rests on a simple logic: IMM60 sounds the immune alarm, while pembrolizumab removes the molecular brakes that tumors use to silence the responding cells.

Safety was the trial’s central question, and the answer was reassuring. No dose-limiting toxicities were observed at any of the doses tested, and the study did not need to define a maximum tolerated dose, the ceiling that phase I trials exist to find. Treatment-related adverse events did occur, affecting ten of the fourteen treated patients, or seventy-one percent, but every one of them was graded as mild or moderate, meaning grade one or two on the standard toxicity scale, and all were self-limiting. For a drug designed to deliberately provoke the immune system, the absence of severe inflammatory side effects is a notable achievement, since excessive immune activation has derailed many immunotherapy candidates before them.

The pharmacokinetic data, which track how the drug moves through the body, showed clean, predictable behavior. Exposure increased in proportion to dose, with the maximum plasma concentration showing a strong linear fit across dose levels, and the drug lingered in circulation with a mean residence time of about seven hours. That predictability matters enormously for a first-in-human agent, because it means clinicians can anticipate how the body will handle each dose rather than contending with erratic spikes or unexpected accumulation. The liposomal delivery appears to have tamed a molecule that, in its earlier form, was notoriously difficult to manage pharmacologically.

More important than how the drug circulated was whether it engaged its biological target, and here the trial provided direct molecular evidence. Within twenty-four hours of infusion, the researchers observed downregulation of the iNKT cell T cell receptor on the surface of circulating cells, a well-recognized sign that the cells have encountered their target ligand and internalized their sensor, confirming that IMM60 reached and stimulated its intended audience in living patients. Alongside this, the drug triggered a measurable wave of chemokines, the signaling molecules that guide immune cells to sites of inflammation and tumors. Monocyte chemoattractant protein-1, known as MCP-1 or CCL2, peaked at twenty-four hours with a geometric mean fold-change of 4.2 times baseline, a statistically significant rise. Interferon-gamma-inducible protein 10, or IP-10, rose faster, peaking at four hours with a 2.4-fold increase, also statistically significant.

Notably, the broad family of pro-inflammatory cytokines, the molecules most associated with the dangerous systemic immune storms that can accompany overzealous immunotherapy, showed no consistent elevation over baseline. This pattern, a targeted rise in chemokines that recruit immune cells without a indiscriminate inflammatory surge, is precisely the profile a rational iNKT agonist should produce. It suggests the drug can orchestrate immune traffic toward tumors while sparing patients the collateral damage of systemic inflammation, a balance that has been the holy grail of this therapeutic class since alpha-galactosylceramide first entered human testing years ago.

On the clinical side, the trial was small and early-stage, so dramatic tumor shrinkage was never the realistic expectation, particularly in a population this heavily pretreated. Even so, the signals were encouraging. Stable disease was the best overall response in the majority of assessed patients, and when the investigators examined individual tumor lesions, they found reductions in thirty percent of the lesions evaluated. Among these was a patient with melanoma whose cancer had resisted both BRAF and MEK inhibitor targeted therapy and PD-1 checkpoint blockade, one of the hardest treatment scenarios in modern oncology. Median progression-free survival across the treated group was 2.9 months, a modest figure that nonetheless reflects the refractory nature of the disease in these patients and the fact that the trial’s dose-escalation design was built to find a safe dose, not to maximize efficacy.

The authors conclude that liposomal IMM60 is well tolerated, shows clear evidence of iNKT cell target engagement and early chemokine induction, and produced signs of disease control in heavily pretreated and PD-1-refractory patients, findings they say support further evaluation of the drug in combination with checkpoint inhibition. The trial, sponsored and funded by iOx Therapeutics and conducted at sites including the Churchill Hospital in Oxford and Hammersmith Hospital in London, was prospectively registered in January 2021. As with any phase I study, the road ahead is long: larger trials will need to determine whether the immune activation seen in blood tests translates into meaningful extension of survival, and which doses and schedules best combine IMM60 with checkpoint blockade. But for a therapeutic concept that has struggled for years to make the leap from laboratory promise to clinical reality, this first-in-human dataset offers something precious: proof that a next-generation iNKT agonist can be given safely to cancer patients, can be seen doing its molecular job, and may be stirring the immune system in tumors that have run out of options.

Subject of Research: A first-in-human phase I trial of the liposomal iNKT cell agonist IMM60 with or without pembrolizumab in advanced melanoma and non-small cell lung cancer

Article Title: IMP-MEL: a phase I first-in-human study of IMM60 with or without pembrolizumab in advanced melanoma and non-small cell lung cancer (NSCLC)

Article References: Coupe, N., Kramer, R., Pinato, D. J., Middleton, M., Gileadi, U., Thompson, D., McJannett, N., Santo, C. D., Poe, R., & Walters, I. (2026). IMP-MEL: a phase I first-in-human study of IMM60 with or without pembrolizumab in advanced melanoma and non-small cell lung cancer (NSCLC). Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08980-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08980-8

Keywords: IMM60, iNKT cells, cancer immunotherapy, melanoma, non-small cell lung cancer, pembrolizumab, phase I trial, liposomal formulation, alpha-galactosylceramide, CD1d, checkpoint inhibitor, chemokines

The two patients described in the report shared several characteristics that are generally associated with poorer outcomes in colorectal cancer. Their disease had recurred and spread to distant sites, and one of the tumors carried the BRAF V600E mutation, a genetic alteration linked to aggressive behavior and resistance to many therapies. Most strikingly, immunohistochemical analysis of tumor samples obtained at surgical resection revealed markedly reduced expression of HLA class I molecules on the surface of the tumor cells. HLA-I proteins are the molecular display stands that present fragments of tumor antigens to cytotoxic T cells, the primary assassins recruited by checkpoint blockade. When these molecules are lost or downregulated, T cells essentially cannot see the tumor, a mechanism considered one of the major routes by which cancers escape immunotherapy.

This is where the biology becomes genuinely intriguing. The very alteration that blinds T cells, the loss of HLA-I expression, is precisely the signal that activates natural killer cells. NK cells are innate lymphocytes that patrol the body looking for cells that have dropped their self-identifying HLA molecules, a tactic commonly used by virus-infected cells and malignant cells alike. In other words, the tumor in these patients had traded invisibility to T cells for visibility to NK cells. The Genoa-based team, including corresponding authors Emanuela Marcenaro, Mariella Della Chiesa and Simona Sivori, hypothesize that this trade-off may have created a therapeutic window that pembrolizumab was able to exploit, even though pembrolizumab is conventionally understood as a drug that reinvigorates exhausted T cells.

The mechanism by which a T-cell-directed drug might unleash NK cells centers on a receptor-ligand pair more often discussed in the context of T-cell biology. Examination of the resected tumor samples showed that the tumor cells expressed PD-L1, the ligand for the PD-1 checkpoint receptor, and that a substantial fraction of the tumor-infiltrating NK cells themselves carried PD-1 on their surface. PD-1 expression on NK cells has been reported in several tumor settings and is generally interpreted as a sign of functional exhaustion, a brake placed on the killer cells by the immunosuppressive tumor microenvironment. If NK cells in these tumors were being restrained through the PD-1 pathway, then pembrolizumab, by blocking PD-1, could in principle release that brake and restore NK-cell-mediated tumor killing.

This interpretation offers a coherent explanation for a clinical outcome that would otherwise be difficult to reconcile. Microsatellite instability generates abundant neoantigens and typically produces tumors that are densely infiltrated by immune cells, which is why MSI-high metastatic colorectal cancer is the one molecular subtype for which pembrolizumab is an approved first-line option. However, the markedly reduced HLA-I expression observed in these two patients should have prevented cytotoxic T cells from recognizing any of those neoantigens. The durable responses achieved under pembrolizumab treatment therefore suggest that an HLA-independent effector mechanism was at work, and the presence of PD-1-positive NK cells within the tumor, combined with PD-L1-positive tumor cells, provides a plausible cellular and molecular substrate for such a mechanism.

The findings carry practical implications that extend beyond the two cases themselves. The authors propose that assessing both PD-L1 and HLA-I expression on tumor cells at diagnosis could help identify which patients stand to benefit most from pembrolizumab, used alone or in combination with inhibitors of HLA-I-specific inhibitory NK receptors. This second component of the proposal draws on a well-characterized layer of NK-cell regulation. NK cells bear inhibitory receptors that recognize specific HLA class I allotypes and keep the killer cells in check as long as those molecules are present on healthy tissue. Tumors that retain partial HLA-I expression can still co-opt these inhibitory pathways to dampen NK attack, and drugs that block these HLA-I-specific inhibitory receptors are being explored as a way to fully unleash NK-cell activity. In a tumor with near-total HLA-I loss, such combination strategies could theoretically deepen the NK-cell response that checkpoint blockade alone initiates.

It is important to emphasize the limits of the evidence. This is a brief report describing two patients, and the authors themselves are careful to frame their conclusions as hypothesis-generating rather than definitive. The observation that PD-1-positive NK cells were present in the tumor microenvironment, and that tumor cells expressed PD-L1, is consistent with a model in which PD-1/PD-L1 blockade contributed to NK-cell-mediated antitumor activity, but it does not prove causation. Direct demonstration would require functional studies showing that NK cells isolated from such tumors kill autologous tumor targets in a manner enhanced by PD-1 blockade, as well as larger cohorts in which HLA-I status, PD-L1 expression and NK-cell infiltration are systematically correlated with clinical outcomes. The authors explicitly call for further investigation in larger and multicenter patient cohorts to test these ideas.

Even so, the report arrives at a moment of intense interest in the role of innate immunity in checkpoint inhibitor responses. HLA-I loss is increasingly recognized as a common mechanism of acquired resistance to PD-1 and PD-L1 inhibitors across tumor types, and it has traditionally been viewed as an almost uniformly bad prognostic sign. Studies in melanoma and lung cancer have shown that tumors losing HLA-I under immune pressure often escape T-cell control, and strategies to restore antigen presentation are an active area of drug development. The Genoa study flips this narrative in an interesting way for microsatellite-unstable colorectal cancer, suggesting that in the right immunological context, HLA-I downregulation may redirect the burden of tumor control from the adaptive to the innate immune system, and that checkpoint blockade may have a role in supporting that innate response.

The study also highlights the value of careful immunophenotyping of tumor specimens in patients who respond unexpectedly well or unexpectedly poorly to immunotherapy. Both patients in the report gave written informed consent under a protocol approved by the Ethics Committee of the Liguria Region in Genoa, and their tumor samples, obtained at surgical resection, allowed the team to characterize HLA-I expression, PD-L1 expression and the phenotype of tumor-infiltrating lymphocytes at a level of detail that routine clinical testing would not capture. As immunotherapy expands into new settings, this kind of granular analysis of exceptional responders has repeatedly proven to be one of the most productive routes to new biological insight, and the present report follows that tradition.

For patients with metastatic colorectal cancer, the immediate clinical message is one of cautious optimism rather than practice change. Pembrolizumab remains the standard of care for MSI-high metastatic disease, and nothing in this report alters that. What the study adds is a potential explanation for why some patients within this category do dramatically better than others, and a concrete, testable biomarker strategy: measuring HLA-I and PD-L1 on tumor cells at diagnosis, and perhaps assessing NK-cell infiltration and PD-1 expression, could eventually help oncologists predict who will benefit from pembrolizumab alone and who might need combination approaches that engage NK cells more directly. If larger studies confirm the hypothesis raised by these two cases, the long-standing division of labor in cancer immunology, in which T cells are seen as the primary effectors of checkpoint blockade and NK cells as supporting actors, may need to be redrawn for at least one important tumor type.

Subject of Research: NK-cell-mediated response to PD-1 blockade in HLA-I-deficient microsatellite-unstable metastatic colorectal cancer

Article Title: Response to pembrolizumab in metastatic colorectal cancer with microsatellite instability and markedly reduced HLA-I expression suggests NK cell involvement

Article References: Provinciali, N., Giordano, C., Obino, V., Bozzo, M., Rutigliani, M., Candiani, S., Carlomagno, S., Pesce, S., Greppi, M., Ciferri, E., Buttiron Webber, T., Paleari, L., Barberis, A., Filauro, M., Clavarezza, M., Marcenaro, E., Della Chiesa, M., DeCensi, A., & Sivori, S. (2026). Response to pembrolizumab in metastatic colorectal cancer with microsatellite instability and markedly reduced HLA-I expression suggests NK cell involvement. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04594-7

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04594-7

Keywords: NK cells, colorectal cancer, microsatellite instability, pembrolizumab, PD-1/PD-L1 blockade, HLA-I expression, immune-checkpoint inhibitors, tumor immunology, immunotherapy, BRAF V600E, cancer immunotherapy, tumor microenvironment

The trial, known as KEYNOTE-966, enrolled 1,069 patients between October 2019 and June 2021 across 175 medical centres in the Asia-Pacific region, Europe, North America and South America. Participants had untreated, histologically confirmed unresectable locally advanced or metastatic biliary tract cancer, including extrahepatic cholangiocarcinoma, gallbladder cancer and intrahepatic cholangiocarcinoma. They were randomly assigned in equal measure to receive either pembrolizumab or a saline placebo alongside standard gemcitabine and cisplatin, with neither patients nor treating investigators knowing which arm they occupied. Pembrolizumab, an antibody that blocks the programmed cell death protein 1, or PD-1, receptor on T cells, is designed to release a molecular brake that tumours exploit to evade immune destruction.

When the protocol-specified final analysis was reported, with a median follow-up of 25.6 months, the pembrolizumab combination had delivered a statistically significant and clinically meaningful improvement in overall survival: a median of 12.7 months compared with 10.9 months for chemotherapy plus placebo, corresponding to a 17 percent reduction in the risk of death. The new report, published in eClinicalMedicine, extends that picture with a median study follow-up of 36.6 months, roughly eleven months of additional observation. At the updated data cutoff of November 2023, median overall survival remained 12.7 months in the pembrolizumab group versus 10.9 months in the placebo group, with a hazard ratio of 0.86, indicating that the survival advantage persisted essentially undiminished over time.

The longer follow-up also sharpened the portrait of long-term survivors. At 24 months, an estimated 25 percent of patients in the pembrolizumab arm were alive compared with 19 percent in the control arm; at 36 months the figures were 13 percent and 11 percent respectively. Approximately 15 percent of participants in both groups remained alive beyond three years, a striking finding in a disease where metastatic five-year survival has historically languished below 5 percent. The investigators caution that the number of patients still at risk in the tail of the survival curves is small, making precise comparisons at these late time points difficult, but the persistence of a hazard ratio favouring pembrolizumab throughout follow-up suggests the treatment benefit is genuinely preserved rather than an artefact of early curve separation.

Progression-free survival, the time until disease worsens or death, also continued to favour the immunotherapy combination, with a median of 6.5 months versus 5.6 months and a hazard ratio of 0.85. Interestingly, the objective response rate, the proportion of patients whose tumours shrank measurably, was identical between arms at 29 percent, a reminder that in immunotherapy the most meaningful gains often come not from shrinking more tumours but from controlling them for longer. That interpretation is borne out by the duration of response: among patients who did respond, responses lasted a median of 8.3 months with pembrolizumab versus 6.9 months with placebo, and at 24 months, 18 percent of responses in the pembrolizumab arm were still ongoing compared with just 7 percent in the placebo arm. The number of patients completing the full 35 cycles, roughly two years, of pembrolizumab also grew since the final analysis, while no comparable increase occurred in the placebo group.

Safety data accumulated over the extended follow-up brought no unpleasant surprises. Nearly all patients in both arms experienced some adverse event, most commonly the neutropenia and anaemia expected from cisplatin-based chemotherapy, and the rates of severe grade 3 or 4 events remained stable at around 70 percent in each group. Immune-mediated adverse events, the characteristic toxicities of checkpoint inhibitors, arose in 25 percent of pembrolizumab recipients versus 15 percent of placebo recipients, with hypothyroidism and pneumonitis the most frequent. Six additional patients in the pembrolizumab arm experienced severe immune-mediated events during the extended follow-up, including gastritis, haemolytic anaemia and single cases of colitis, hepatitis, hypophysitis and pneumonitis, but the overall profile remained comparable to the final analysis, with no new safety signals identified. Deaths attributable to treatment-related events were unchanged at 2 percent in the pembrolizumab group.

The updated results land alongside three-year data from the rival TOPAZ-1 trial, which tested a different checkpoint inhibitor, durvalumab, an antibody targeting PD-L1 rather than PD-1, on the same chemotherapy backbone. TOPAZ-1 reported a hazard ratio of 0.74 for overall survival, with medians of 12.9 versus 11.3 months, after a median follow-up of 41.3 months. The two trials differ in instructive ways: TOPAZ-1 limited gemcitabine to eight cycles whereas KEYNOTE-966 allowed it to continue until progression or intolerance, and KEYNOTE-966 was larger, with 1,069 participants compared with 685, including substantially more patients enrolled outside Asia. Notably, the survival benefit in KEYNOTE-966 was consistent in the large non-Asian subgroup, strengthening confidence that the finding generalises across diverse populations and healthcare systems.

Quality-of-life analyses, reported previously from the trial, add an important dimension: adding pembrolizumab to the chemotherapy regimen did not produce a clinically meaningful deterioration in patient-reported functioning or well-being. The authors of the new analysis acknowledge a caveat here, namely that existing quality-of-life instruments were largely designed for cytotoxic drugs and may not fully capture the distinct experience of immune-mediated toxicities, and they call for better standardisation of patient-reported outcome assessment in future biliary tract cancer trials so that survival gains can be weighed against the lived experience of treatment.

The study is not without limitations. Because the primary survival endpoint was already met at the final analysis, the updated comparisons are descriptive and exploratory, with no formal hypothesis testing or alpha allocation. The shrinking at-risk population with longer follow-up makes late survival estimates imprecise, and the biological characteristics that distinguish the long-term survivors, whether tumour molecular features, disease burden, or responses to subsequent therapies, were not specifically evaluated. The authors argue that characterising this favourable subgroup could inform future patient selection and point the way toward rational combinations with novel agents, an urgent priority given how poor the prognosis remains even with immunotherapy on board.

Nevertheless, the message for clinical practice is clear and now firmly anchored in three years of evidence: pembrolizumab plus gemcitabine and cisplatin stands as a validated standard first-line treatment for previously untreated unresectable or metastatic biliary tract cancer. Together with TOPAZ-1, the trial establishes that immune checkpoint blockade has earned a permanent place in the frontline management of one of medicine’s deadliest cancers, converting a uniformly grim prognosis into one where a meaningful minority of patients can now anticipate years, not months, of survival.

Subject of Research: Long-term phase 3 trial results of pembrolizumab combined with gemcitabine and cisplatin chemotherapy for advanced biliary tract cancer

Article Title: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial

Article References: Ueno, M., Yoo, C., Ren, Z., Furuse, J., Kelley, R. K., Chan, S. L., Edeline, J., Klümpen, H.-J., Yau, T., Verslype, C., Ozaka, M., Bouattour, M., Park, J. O., Vogel, A., Valle, J. W., Starkopf, L., Malhotra, U., Siegel, A. B., Qin, S., … Elias, R. (2026). Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial. eClinicalMedicine, 100, Article 104213. https://doi.org/10.1016/j.eclinm.2026.104213

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104213

Keywords: biliary tract cancer, cholangiocarcinoma, pembrolizumab, KEYNOTE-966, immunotherapy, PD-1 inhibitor, gemcitabine, cisplatin, phase 3 trial, overall survival, checkpoint inhibitor, oncology